Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site. # Intelligencia AI ## Sitemaps - [XML Sitemap](https://www.intelligencia.ai/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [ESMO 2026 Clinical Programs in Focus](https://www.intelligencia.ai/esmo-2026-top-oncology-therapies/) - Discover 10 promising oncology clinical programs identified by Intelligencia AI for ESMO 2026, highlighting novel mRNA vaccines, ADCs, and cell therapies. - [The Insight Drop | Beyond CD20: Autoimmunity’s Race for Deeper B-Cell Depletion](https://www.intelligencia.ai/beyond-cd20-deeper-b-cell-depletion/) - Explore how autoimmune R&D is moving beyond CD20 toward CD19, BCMA and CD38, and why deeper B-cell depletion may reshape durable immune-reset strategies. - [2nd Internal GenAI H4ckAthon: Building a Smarter, AI-Driven Future at Intelligencia](https://www.intelligencia.ai/2nd-internal-genai-h4ckathon-building-a-smarter-ai-driven-future-at-intelligencia-ai2nd-h4ckathon/) - Exploring how Generative AI can transform everyday workflows was the focus of our recent internal GenAI Hackathon. Teams across the organization came together to identify practical opportunities for automation, efficiency, and smarter ways of working using GenAI tools. The energy in the room was outstanding. Ideas were shared, prototypes were built, and the level - [The Insight Drop | From Control to Reset: Autoimmune R&D Is Changing the Endgame ](https://www.intelligencia.ai/the-insight-drop-autoimmune-rd-immune-reset/) - Immune reset is reshaping autoimmune R&D as CAR-T, T-cell engagers and in-vivo approaches challenge chronic immunomodulation. - [From Conviction to Evidence: A Conversation with a Senior Director of Search & Evaluation](https://www.intelligencia.ai/conviction-to-evidence-biopharma-deal-decisions/) - See how a corporate development leader uses Intelligencia AI to evaluate assets faster, challenge bias, and make more defensible deal decisions. - [The Insight Drop | When AI Sounds Right: The Hidden Risk in Pharma R&D](https://www.intelligencia.ai/hidden-risk-ai-pharma-rd/) - AI can produce credible answers in pharma R&D while missing critical evidence. Explore the hidden risk of incomplete AI-driven analysis. - [AI in Pharma: Why Information Matters More Than Models](https://www.intelligencia.ai/ai-in-pharma-why-information-matters-more-than-models/) - Why pharmaceutical AI struggles with complex decisions and why structured data, domain expertise and connected knowledge matter more than model power. - [Clinical Success Is No Longer One Number](https://www.intelligencia.ai/clinical-success-is-no-longer-one-number/) - See why program-level benchmarks reveal hidden clinical development risks that traditional therapeutic area benchmarks often fail to capture. - [Intelligencia AI Named to the Inc. 5000 2026 List of America's Fastest-Growing Private Companies](https://www.intelligencia.ai/intelligencia-ai-inc-5000-2026/) - Intelligencia AI is proud to announce its inclusion on the 2026 Inc. 5000 list for the third consecutive year, ranking among America's fastest-growing private companies. The company was also recognized within the Artificial Intelligence and Data industry, ranking No. 110. This recognition reflects the growing impact of Intelligencia AI's decision intelligence platform, helping pharmaceutical and - [Machine learning approaches to predict drug efficacy and toxicity in oncology](https://www.intelligencia.ai/ml-oncology-drug-efficacy-toxicity/) - Discover how machine learning algorithms predict drug efficacy and toxicity in oncology, utilizing molecular and disease data to forecast FDA approvals. - [The Impact of Clinical Development Decisions on Time to Market and Development Risk in Oncology](https://www.intelligencia.ai/clinical-development-decisions-oncology/) - Authors: Matthew Furlow, PhD, Associate Principal at ZS; Andreas Dimakakos, PhD, MBA, PMP, Director of Scientific Insights, Intelligencia AI; Evgenia Kyriakidou, Business Insights Associate, Intelligencia AI; Elpiniki Georgiou, PhD, Senior Data Analyst, Intelligencia AI; Contributors: Joshua Hattem, Principal, R&D Advisory Lead, ZS and Panos Karelis, Director of Insights Excellence, Intelligencia AI Key Findings Every month - [The Insight Drop | B7-H3 (CD276): The ADC Race to Unlock a High-Momentum Target](https://www.intelligencia.ai/b7-h3-cd276-adc-era-clinical-development-landscape/) - B7-H3 has entered its ADC-led era. Explore the target’s clinical evolution, modality shift, Phase 3 wave, and what will determine its path to approval. - [Intelligencia AI - Industry Partners Boston Roundtable](https://www.intelligencia.ai/intelligencia-ai-industry-partners-boston-roundtable/) - We will be hosting an executive roundtable in Boston with industry leaders to discuss the evolving challenges of clinical development.It will be a great opportunity to exchange perspectives, explore emerging trends, and hear firsthand how teams across the industry are tackling complex development decisions. These insights will directly shape how we build! Sessions like this - [EP3M Summit Executive Project, Portfolio, Program & Portfolio Management Summit](https://www.intelligencia.ai/ep3m-executive-decision-making-conference/) - Intelligencia AI is proud to be a sponsor and exhibitor at the 2026 EP3M Summit in Boston, where the pharma and biotech industry's top portfolio, program, and project management executives gather to tackle the most pressing challenges in pipeline prioritization, data-driven decision making, and R&D strategy. Stop by our booth to connect with our team - [The Insight Drop | Oral GLP-1: The Next Distribution Shift—But Not the Torch Pass Yet](https://www.intelligencia.ai/oral-glp1-next-distribution-shift/) - The oral GLP-1 wave is real, but obesity's highest-confidence bets remain injectable. Explore the data behind the shift. - [Marcus Evans: Unlocking Smarter Business Decisions for Pharma and Biotech](https://www.intelligencia.ai/marcus-evans-unlocking-smarter-business-decisions-for-pharma-and-biotech/) - Intelligencia AI is excited to announce that we will be attending the Marcus Evans AI, Forecasting, Insights and Analytics for Smarter Decisions in Pharma event, which will take place in the city of London, UK this coming September! We look forward to engaging with industry leaders and exploring innovative strategies that can revolutionize decision-making processes - [China Biotech in 2026: Why the China Discount Is Gone and What Comes Next](https://www.intelligencia.ai/insights-china-biotech-discount-newco-model-2026/) - Why the structural discount on China-originated biotech assets has closed, and what the NewCo model, parallel pipelines, and AI mean for valuation. - [The Insight Drop | KRAS Targeting Has Entered Its Second Era: From G12C Breakthrough to a Multi-Mutation Race](https://www.intelligencia.ai/kras-second-era-beyond-g12c/) - KRAS is evolving beyond G12C. Explore the rise of non-G12C and pan-G12 programs, shifting investment trends, and the future of KRAS targeting. - [ASCO 2026: A Focus on Advancements and Innovations in Oncology](https://www.intelligencia.ai/asco-2026-clinical-programs-in-focus/) - TL;DR ASCO 2026 has evolved into a critical strategic event for biopharma executives, investors, BD teams, and clinical leaders seeking signals about where oncology innovation and competitive dynamics are heading. Interpreting oncology data now requires more than scientific expertise; meaningful assessment increasingly depends on understanding regulatory precedent, competitive positioning, biomarker strategy, and historical development benchmarks. - [The Insight Drop | Autoimmune CAR-T: The Fastest Modality Shift We’ve Seen in Immunology—Still Ahead of Proof](https://www.intelligencia.ai/the-insight-drop-autoimmune-car-t-the-fastest-modality-shift-weve-seen-in-immunology-still-ahead-of-proof/) - TL;DR Autoimmune CAR-T has gone from niche experiment to strategic category in just a few years — with trial activity nearly zero before 2022 and now approaching 47 programs annually by 2025. Lupus leads the indication race (36.8% of programs), followed by MS and scleroderma, but the indications closest to pivotal proof are myasthenia gravis - [The Insight Drop | ctDNA Endpoints in Oncology: Rising Trial Adoption, Limited Validation—and a Clear Path to Credibility](https://www.intelligencia.ai/the-insight-drop-ctdna-endpoints-in-oncology-rising-trial-adoption-limited-validation-and-a-clear-path-to-credibility/) - TL;DR ctDNA adoption in oncology trials has grown significantly over the past decade. Despite growing interest, ctDNA remains overwhelmingly a secondary or exploratory endpoint rather than a primary endpoint. Only four oncology trials in our dataset use ctDNA as a primary endpoint. Adoption is concentrated in solid tumors, particularly NSCLC, HER2-negative breast cancer, colorectal cancer, - [Ionis and Intelligencia AI: Transforming PTRS Benchmarking Into a Strategic Portfolio Capability](https://www.intelligencia.ai/ionis-intelligencia-ai-ptrs-benchmarking-portfolio-optimization/) - Ionis and Intelligencia AI transform PTRS benchmarking into a dynamic, transparent portfolio capability using data-driven, asset-specific insights. - [From Data to Decisions: How AI and Expert Insight Advanced Tumor Type Prioritization Strategy](https://www.intelligencia.ai/ai-driven-ptrs-tumor-prioritization-strategy/) - Learn how ZS and Intelligencia AI used explainable AI-driven PTRS to prioritize solid tumor investments, reduce manual effort, and accelerate strategic pharma decisions. - [Better Benchmarking Improves Drug Development Decision-Making - Here's How](https://www.intelligencia.ai/better-benchmarking-elevates-pharma-decision-making/) - Authors: Aris Galanopoulos, Senior Product Manager and Iliana Kerzeli, Senior Customer Success Associate Why is benchmarking crucial in the pharmaceutical industry? Benchmarking, an essential tool in drug development, allows companies to assess the likelihood of a drug making it through clinical development and receiving regulatory approval. While several methods exist to assess a drug's probability - [Inside Intelligencia AI: A Day in The Life With Eva Loizou](https://www.intelligencia.ai/inside-intelligencia-ai-a-day-in-the-life-with-eva-loizou/) - We never tire of mentioning how instrumental our people are to our success—because it is so incredibly true. Get a glimpse into the day in the life of our team. - [5 Portfolio Management Lessons Learned from the Strategic PPM for Pharma Conference](https://www.intelligencia.ai/5-portfolio-management-lessons-learned/) - 5 Portfolio Management Lessons Learned: conference takeaways on better decisions, focusing the “crux,” early optionality, AI-enabled objectivity and governance - [The Insight Drop | NSCLC Is the ADC Battlefield—and Topo-I Is the New Default](https://www.intelligencia.ai/nsclc-adc-battlefield-topo-i-payloads-strategy/) - NSCLC is the ADC battleground, with Phase 3 competition rising and convergence on Topo-I payloads and TROP-2 targets shaping strategy and risk. - [Incorporate AI to Identify High-Potential Antibody Assets for Strategic Acquisition](https://www.intelligencia.ai/ai-to-identify-high-potential-antibody-assets/) - Objective A biotech company specializing in oncology therapies sought to acquire a late-stage asset in the antibody space to complement and strengthen its existing pipeline. The goal was to identify innovative, high-potential programs outside the typical big pharma landscape. Approach To ensure an objective, data-driven asset selection process, we leveraged our AI-driven Probability of Technical - [Neudata: London Data Summit](https://www.intelligencia.ai/neudata-london-data-summit/) - Europe's premier alternative and market data event The investment industry’s premier alternative and market data event returns to London in 2025. Join an audience of public and private investment funds across a diverse range of trading strategies, for a day of insightful content and unmatched networking. Whatever your data needs and challenges, our London Summit - [The Pharma PPM Toolbox](https://www.intelligencia.ai/the-pharma-ppm-toolbox/) - Welcome to the Pharma PPM Toolbox Conference which is an event tailored for professionals in the pharmaceutical industry who specialize in project and portfolio management (PPM). Its primary focus is on: sharing knowledge, strategies and best practices to improve the management of pharmaceutical projects and portfolios In times of both great challenges and opportunities, our - [Boston Paris Biotechnology Summit](https://www.intelligencia.ai/boston-paris-biotechnology-summit/) - The Summit is a must-attend, hand-crafted content, 250 attendees, quality international networking … The Summit was co-founded in 2016 by Shahin & Soheila Gharakhanian. The Boston/Paris Biotechnology Summit® is an exclusive, Trans-Atlantic Bridge designed to foster innovative synergies between biotech and pharma companies, healthcare-focused cities and regional clusters, institutional, philanthropic and strategic investors. The Summit®’s intent is to - [Panathēnea 2026: Intelligencia AI at Athens LifeTech Park LifeSciences Day](https://www.intelligencia.ai/panathenea-2026-intelligencia-ai-at-athens-lifetech-park-lifesciences-day/) - Intelligencia AI is proud to be part of Panathēnea 2026, one of the most influential gatherings of investors, founders, and technology leaders hosted in Athens. As participants in the Athens LifeTech Park LifeSciences Day, the flagship life sciences side event of Panathēnea 2026, our very own Evangelia Loizou, Ph.D. took the stage as a panelist - [1st Internal GenAI H4ckAthon: Building a Smarter, AI-Driven Future at Intelligencia](https://www.intelligencia.ai/1st-internal-genai-h4ckathon-building-a-smarter-ai-driven-future-at-intelligencia/) - At Intelligencia AI, we believe that transforming drug development starts from within. Our first internal GenAI Hackathon brought teams from across the organization together to explore how Generative AI can reshape everyday workflows, drive smarter automation, and unlock new levels of efficiency in how we work. From identifying practical use cases to building working prototypes, - [Health Tech Company Intelligencia AI Appoints Scientific Advisory Board Chair](https://www.intelligencia.ai/health-tech-company-intelligencia-ai-appoints-scientific-advisory-board-chair/) - Pharmaceutical industry leader, Névine Zariffa, to assume new leadership role Leading healthcare technology company Intelligencia AI™ recently appointed pharmaceutical industry leader Névine Zariffa as its Scientific Advisory Board Chair. Formalizing the Scientific Advisory Board demonstrates the company’s investment in growth and signals the next chapter of maturity for the 2017 New York-founded company. “Ms. Zariffa’s deep clinical development expertise - [Intelligencia AI Awarded U.S. Patent for Its Accurate and Transparent Probability of Drug Success Assessments](https://www.intelligencia.ai/intelligencia-ai-awarded-u-s-patent-for-its-accurate-and-transparent-probability-of-drug-success-assessments/) - Health tech company pioneers de-risking clinical development through patented algorithms, technology and use of artificial intelligence - [Inside Intelligencia AI: A Day in The Life With Andreas Dimakakos](https://www.intelligencia.ai/employee-blog-andreas-dimakakos/) - We never tire of mentioning how instrumental our people are to our success, because it is so incredibly true. Everything we have achieved and continue to do at Intelligencia AI and in the industry is a result of our dedicated, intelligent, and motivated professionals, who identify areas of opportunity and tackle challenges every day with - [De-Risking Oncology Combination Therapies with Data-Driven Insight](https://www.intelligencia.ai/oncology-combination-therapy-success-data-insights/) - Learn how Intelligencia AI and GSK use clinical data to de-risk oncology R&D by predicting combination therapy success from early monotherapy signals. - [5 Takeaways From the Corvus Digi-Tech Pharma and AI Summit](https://www.intelligencia.ai/takeaways-corvus-digi-tech-pharma-and-ai-summit/) - Intelligencia AI’s business development team had the opportunity to attend and sponsor the recent Corvus Digi-Tech Pharma & AI Summit in London. Here are 5 key takeaways. - [Insights from ASCO 2024: What AI-Driven PTRS Assessments Unveil](https://www.intelligencia.ai/asco-2024-insights-ptrs/) - Insights from ASCO 2024 - [Spotlight on Tomorrow’s Breakthroughs: An ESMO 2025 Preview](https://www.intelligencia.ai/esmo-2025-watchlist/) - Our ESMO watchlist methodology is grounded in our AI-driven PTRS framework, which combines quantitative modeling with expert interpretation to identify the most promising oncology programs. - [ESMO 2025: Results That Signal Clinical and Scientific Momentum](https://www.intelligencia.ai/esmo-2025-results-that-signal-clinical-and-scientific-momentum/) - Several programs featured in our ESMO 2025 Watchlist released data that collectively reflect a deeper understanding of disease biology, improved drug design, and expanding treatment potential across diverse tumor settings. - [ASH as a Showcase for Cutting-Edge Science and Clinical Progress in Hematology](https://www.intelligencia.ai/ash-2025-watchlist-cutting-edge-science-clinical-progress-hematology/) - ASH highlights emerging hematology innovations, while Intelligencia AI identifies programs with high clinical and strategic importance. - [The Insight Drop | Modality Momentum in Oncology](https://www.intelligencia.ai/insight-drop-emerging-oncology-modalities/) - We’ve been spending a lot of time lately going deep into our clinical development data—not just running models, but wondering: Where are the less obvious opportunities hiding? here are the assumptions that might need updating? That digging has surfaced some insights we thought you'd find valuable. This is the first in a series of The - [The Insight Drop | GLP-1: The Target Reigniting an Entire Therapeutic Area](https://www.intelligencia.ai/glp-1-target-shifting-landscape-metabolic-rd/) - GLP-1 drugs are transforming metabolic disease R&D, but success depends on differentiation in a crowded, competitive landscape. - [The Insight Drop | The Next Generation of I&I: Beyond TNF, Into IL-17/23](https://www.intelligencia.ai/next-gen-immunology-inflammation-il17-il23/) - Discover how I&I therapies are evolving from TNF inhibitors to next-gen IL-17 and IL-23 treatments with improved precision and safety. - [The Insight Drop | Line of Treatment: A Strategic Lever in Oncology Drug Development](https://www.intelligencia.ai/oncology-line-of-treatment-strategy-benchmarks/) - Analyze 6,000+ oncology programs to see how Line of Treatment impacts trial speed, transition rates, and the probability of regulatory approval. - [The Insight Drop | Regulatory Designations in Oncology: Signal or Substance?](https://www.intelligencia.ai/regulatory-designations-oncology-success-rates/) - An analysis of over 11,000 oncology programs reveals how Priority Review, Breakthrough, Fast-Track, and Orphan Drug designations impact approval rates and clinical success. - [Accelerating Business Development Decisions in Oncology](https://www.intelligencia.ai/case-study-accelerating-business-development-decisions-in-oncology/) - How a global pharmaceutical company used data and AI to streamline business development activities Key Objectives Develop a high-level view of the oncology market landscapes for 10+ tumor types Construct a comprehensive list of assets and priority screening criteria for business development efforts accounting for parameters such as: the organization’s strategic objectives, mechanism of action - [Enhancing Oncology PTRS Processes With a Cutting-Edge, AI Approach](https://www.intelligencia.ai/case-study-enhancing-oncology-ptrs-processes-with-a-cutting-edge-ai-approach/) - Global biopharma company leverages patented Intelligencia Portfolio OptimizerTM to enhance its scientific and business decision-making Core Challenges Reliant on a resource-intensive and inconsistent process for evaluating phase transition and probability of technical and regulatory success (PTRS). Limited data and lack of objectivity for drug development portfolio go/no-go and investment decisions. Need to support oncology pipeline - [How AI Is Shaping Investment Decisions in Pharma: Discover Real-World Examples](https://www.intelligencia.ai/how-ai-is-shaping-investment-decisions-in-pharma-discover-real-world-examples/) - Mid- to large-tier pharmaceutical and financial industry professionals use AI solutions developed by Intelligencia AI to identify undervalued assets and make better investment decisions. Here are some real-world use cases where we collaborated with our customers to help maximize their return on investment (ROI) and make more informed investment decisions. Identify High-Performing, Promising Early-Stage Assets - [Expedite Confident Investment Decisions in Pharma](https://www.intelligencia.ai/case-study-confident-investment-decisions-in-pharma/) - ZS used Intelligencia AI to cut tumor evaluation from 6 to 2 months, narrowing 60 segments to 10 with precise, data-driven insights. Read the case study. - [Navigating the Oncology Patent Cliff: Strategic Imperatives for Big Pharma](https://www.intelligencia.ai/oncology-patent-cliff/) - Learn how pharma can prepare for the oncology patent cliff, protect revenue, and boost pipelines with data-driven, AI-powered strategies. - [Part 4 | From Principles to Practice: How Intelligencia AI Turns AI-Ready Clinical Data Into a Decision-Making Advantage](https://www.intelligencia.ai/ai-ready-clinical-data-intelligencia-ai/) - See how Intelligencia AI turns public sources into AI-ready clinical data—curated, harmonized, and time-stamped—to improve PTRS, BD&L, and portfolio choices. - [Part 3 | Garbage In, Failure Out: The High Price of Low-Quality Data in Drug Development](https://www.intelligencia.ai/price-of-low-quality-data-drug-development/) - The price of low-quality data can be staggering. Discover why investing in clean, curated data upfront can save time, money, and resources. - [Part 2 | Chaos to Clarity: The Case for Biomedical Data Curation](https://www.intelligencia.ai/biomedical-data-curation-ai/) - Explore why public biomedical data must be curated before AI can extract insights and how expert-driven curation unlocks decision-grade insights. - [Part 1 | What Makes Clinical Development Data “Good”?](https://www.intelligencia.ai/high-quality-clinical-development-data/) - Explore what makes clinical development data reliable, reusable, and AI-ready—from completeness and consistency to curation, ontologies, and context. - [Stop Flying Blind: Here’s How Competitive Landscapes Drive Commercial Success in Pharma](https://www.intelligencia.ai/competitive-landscapes-flying-blind/) - Learn how competitive landscapes inform decisions across pharma R&D and clinical development. Discover how Intelligencia AI enhances them, making them faster, more accurate, and easier to use. - [Drug Development in the Age of shifting global policies: Why Risk, Sequencing, and PTRS Matter More Than Ever](https://www.intelligencia.ai/drug-development-shifting-global-policies-ptrs/) - How global policy shifts are reshaping drug development—why parallel trials, PTRS, and AI-driven risk modeling are now critical for smarter portfolio decisions. - [Executive Summary: Elevate and De-Risk Your Drug Portfolio Strategy With AI](https://www.intelligencia.ai/executive-summary-elevate-and-de-risk-your-drug-portfolio-strategy-with-ai/) - With the right data, the pharmaceutical industry can benefit from artificial intelligence (AI)-based tools in many ways, including decision-making for scientific and business challenges. Introduction In this Pharmaceutical Executive webcast sponsored by Intelligencia AI, industry experts* discussed leveraging AI to quantify better the risks associated with crucial decisions in drug development and the value of - [Intelligencia AI Honored as a Winner in the 2025 Artificial Intelligence Excellence Awards](https://www.intelligencia.ai/intelligencia-ai-honored-as-a-winner-in-the-2025-artificial-intelligence-excellence-awards/) - New York, NY—June 1, 2025—Intelligencia AI is proud to announce that it has been named a winner in the 2025 Artificial Intelligence Excellence Awards, presented by the Business Intelligence Group. This prestigious recognition highlights the company’s commitment to innovation and its contributions to advancing artificial intelligence. Portfolio Optimizer enables portfolio leaders, BD&L professionals and competitive - [The Insight Drop | Routes of Administration: When Convenience Becomes Strategy](https://www.intelligencia.ai/routes-of-administration-strategy-oncology-immunology-neurology-metabolic/) - Route of administration is no longer just formulation. Discover how IV, oral, and subcutaneous delivery shape strategy, approvals, and lifecycle decisions across key therapeutic areas. - [The Insight Drop | Radioligands in Oncology: Explosive Program Growth, Familiar Targets, and a Rapidly Maturing Ecosystem](https://www.intelligencia.ai/radioligands-oncology-growth-targets-ecosystem/) - Explore the rapid growth of radioligands in oncology, key targets like PSMA and SSTR2, and how payload innovation is driving scalable clinical programs. - [The Insight Drop | Bispecific T-Cell Engagers: The Post-2014 Surge, the Myeloma Gravity Well, and the Limits of “Target Rotation”](https://www.intelligencia.ai/bispecific-t-cell-engagers-bites-myeloma-bcma-gprc5d/) - Overview of BiTE evolution since 2014, myeloma dominance (BCMA, GPRC5D), and emerging solid tumor and immunology expansion trends. - [Biotechnology & Artificial Intelligence in Drug Development: Panel Discussion in Athens Metropolitan Expo](https://www.intelligencia.ai/biotechnology-artificial-intelligence-in-drug-development-panel-discussion-in-athens-metropolitan-expo/) - We are excited to announce that Dimitris Skaltsas will be joining as a speaker at Panel 1: "Biotechnology & Artificial Intelligence in Pharmaceutical Development" on Wednesday, June 17, 2026, from 11:15 to 11:45, at Hall 3 (Stand C02/D01), Athens Metropolitan Expo. We look forward to sharing insights on how AI is shaping the future of - [Intelligencia AI - Industry Partners Boston Roundtable](https://www.intelligencia.ai/intelligencia-ai-industry-partners-athens-roundtable-1st/) - We will be hosting an executive roundtable in Boston with industry leaders to discuss the evolving challenges of clinical development.It will be a great opportunity to exchange perspectives, explore emerging trends, and hear firsthand how teams across the industry are tackling complex development decisions. These insights will directly shape how we build! Sessions like this - [Intelligencia AI - Industry Partners Athens Roundtable](https://www.intelligencia.ai/intelligencia-ai-industry-partners-athens-roundtable/) - We will soon be hosting our second Industry Partners Roundtable in Athens with key stakeholders and industry leaders to discuss the latest developments and evolving challenges shaping the future of clinical development. It will be a great opportunity to exchange perspectives, explore emerging trends, and hear firsthand how teams across the industry are navigating complex - [The Insight Drop | MRD as a Primary Endpoint: The Hype Outpaces the Data](https://www.intelligencia.ai/mrd-primary-endpoint/) - Minimal Residual Disease (MRD), an endpoint unique in liquid cancer, is frequently cited as a promising endpoint in drug development. Regulatory agencies, including the FDA, now accept MRD-negativity as a surrogate for long-term outcomes and accelerated approvals in certain cases, and its correlation with improved progression-free survival (PFS) is well documented. While industry interest is - [The Insight Drop | Monotherapy or Combo? Making the Right Bet in Oncology Development](https://www.intelligencia.ai/monotherapy-or-combo-oncology-drug-development/) - Deciding whether to develop a therapy as a monotherapy or combination is one of the most impactful, strategic choices a company can make. Here's what we found. - [The Insight Drop | From Breakthrough to Bottleneck: The Regulatory Journey of JAK Inhibitors](https://www.intelligencia.ai/jak-inhibitors/) - JAK inhibitors were repositioned from frontline agents to later-line use, dramatically impacting both clinical development and investment appetite. Here's what the data shows. - [The Insight Drop | CAR-T in Solid Tumors: The Shift Is Closer Than It Appears](https://www.intelligencia.ai/the-insight-drop-car-t-in-solid-tumors-the-shift-is-closer-than-it-appears/) - Chimeric Antigen Receptor T-cell (CAR-T) therapy remains one of the most transformative innovations in oncology. Here's what the data shows for where it's going next. - [The Insight Drop | Innovation, Bottlenecked: The State of Phase 3 Clinical Development in Alzheimer’s Disease](https://www.intelligencia.ai/phase-3-alzheimers-disease/) - This analysis tracks 19 active Phase 3 programs in AD, covering 16 unique drugs. At first glance, this reflects continued sponsor commitment. See the data here. - [The Insight Drop | Cell Therapy in Multiple Sclerosis: A Market Signal in Search of Proof](https://www.intelligencia.ai/the-insight-drop-cell-therapy-multiple-sclerosis-market-signal/) - Cell therapies in MS are accelerating rapidly—but no program has reached Phase 3. Is this durable innovation or early-stage optionality? - [The Insight Drop | PD-1/VEGF Bispecifics: From China-Driven Breakthrough to Global Reality Check](https://www.intelligencia.ai/pd1-vegf-bispecifics-fda-risk-analysis/) - China approvals propelled PD-1/VEGF bispecifics into global prominence, but FDA-track data exposes OS uncertainty and underestimated late-stage regulatory risk. - [Three Lessons from the European Life Sciences CEO Forum for Biotech and Biopharma](https://www.intelligencia.ai/lessons-european-life-sciences-ceo-forum/) - Three takeaways from the European Life Sciences CEO Forum: selective capital, momentum areas (GLP-1, precision immunology, radiopharma), and partnering shifts - [From AI Pilots to Pharma Impact: Why Deployment, Not Innovation, Determines Success](https://www.intelligencia.ai/ai-pharma-deployment-success/) - Discover why AI success in pharma depends on deployment, governance, data quality, and adoption—not just technology or models. - [Decision Quality in Pharma: Turning Frameworks into Organizational Capability](https://www.intelligencia.ai/decision-quality-pharma-organizational-capability/) - Why decision quality initiatives in pharma often stall—and how AI and institutional knowledge may help sustain better R&D decisions. - [Are Pharma BD Teams Overestimating their Odds?](https://www.intelligencia.ai/pharma-bd-overestimating-odds/) - Probability of success is consistently overestimated in pharma BD. Insights from the Pharma Partnering Summit on how rigorous modeling could reset deals. - [Sailing the Waves of the Basel Healthtech Conference:A Recap and Reflection](https://www.intelligencia.ai/sailing-the-waves-of-the-basel-healthtech-conferencea-recap-and-reflection/) - As we conclude the Basel Healthtech Conference, we reflect on the incredible moments, insightful discussions, and transformative ideas that shaped this extraordinary event! With 515 registered delegates, 805 scheduled meetings, 2 keynotes, and 15 panel sessions, our inaugural Basel Healthtech Conference was an exhilarating two-day journey into the heart of healthtech innovation. Investors, start-ups, growth - [How Artificial Intelligence Improves Risk Assessment in Drug Development](https://www.intelligencia.ai/how-artificial-intelligence-is-improving-risk-assessment-in-drug-development/) - To say that identifying successful drug candidates during development is the 64,000-dollar question is a huge understatement! Much more money - millions, tens, or even hundreds of millions of dollars - rides on picking the winner: the drug that beats the odds and eventually gets approved by the FDA, the EMA, or another regulatory body. - [Want to Use AI? Start by Wrangling Your Data!](https://www.intelligencia.ai/want-to-use-ai-start-by-wrangling-your-data/) - Here is a common misconception: AI is all about the latest, greatest, really cool algorithms. Sure, there is that, but to get the most precise and accurate answers from your algorithms a lot of upfront work needs to go into data wrangling. Experts estimate that up to 80% of the time of deploying AI is - [Data-Backed Probability of Technical and Regulatory Success - Here’s How AI Supports Critical Decisions in Drug Development](https://www.intelligencia.ai/data-backed-probability-of-technical-and-regulatory-success-heres-how-ai-supports-critical-decisions-in-drug-development/) - Drug development is a slow and risky business, now even more so than in the past. Research shows[1] that the average cost of developing a drug from discovery to market entry is about $2.6B and takes roughly 12 years[2]. You will be hard-pressed to find any other products - except nuclear power plants - with similar - [Patented AI Platform Identifies Promising BioPharma Assets](https://www.intelligencia.ai/identify-early-stage-biopharma-assets-probability-of-success/) - The stakes are sky-high for pharmaceutical companies and investors alike. At Intelligencia AI, our methodology offers a clear edge by delivering superior, real-time insights into the probability of success (PoS) for Phase 1 and Phase 2 assets gaining FDA approval. - [AI Explainability Explained | Making AI Models More Transparent](https://www.intelligencia.ai/ai-explainability-explained-making-ai-models-more-transparent/) - One of the biggest challenges with artificial intelligence (AI) might be a very human one. It comes down to the question: how can we trust an algorithm that ingests vast amounts of data, crunches them in some way that most of us don’t understand and then spits out a result that we can’t reconstruct? It - [On Our Radar: Five ASCO Announcements and Updates We're Watching](https://www.intelligencia.ai/on-our-radar-five-asco-announcements-and-updates-were-watching/) - With the 2024 ASCO Annual Meeting kicking off this week in the Windy City, here’s what has caught our eye. and are looking forward to learning and hearing more in the coming days. We will closely follow the #ASCO24 conversations on LinkedIn. With over 5,000 abstracts being published, we highlighted just a handful of what’s to come. - [Inside Intelligencia AI: A Day in The Life With Agamemnon, Senior Data Scientist & Bioinformatician](https://www.intelligencia.ai/employee-blog-series-agamemnon/) - Throughout our “Day in the Life” blog series, we’ll introduce you to our global team and introduce you to the intelligence – our people – behind Intelligencia AI. - [4 Reasons to Attend Conferences for Pharma Decisions Makers and Our 6 Top Picks](https://www.intelligencia.ai/ai-pharmaceutical-conferences/) - Here are some of the top pharmaceutical decision-making conferences you can find us at. - [An Ever-Growing Glossary of Drug Development, Risk Assessment and AI Terms ](https://www.intelligencia.ai/glossary-drug-development-risk-ai/) - In three categories - terms related to drug development, risk assessment and AI - our ever-growing glossary briefly defines terms relevant to drug development, risk assessment and artificial intelligence, helping to put these common terms into plain English. - [Alphabet Soup From POS to PTRS: Drug Development Success Terminology](https://www.intelligencia.ai/drug-development-terms-ptrs-pos/) - Objective and data-driven methods are needed to reliably assess an asset's likelihood of success, inform decision-making and provide a documented, well-vetted strategic and holistic analysis of the risks. Various metrics and combinations are used to assess the risk of individual steps in drug development or to refer to the overall risk of successfully getting a drug approved, priced and sold. - [Inside Intelligencia AI: A Day in The Life With Eleni, Scientific Associate in Clinical Data Excellence](https://www.intelligencia.ai/inside-intelligencia-ai-eleni-clinical-data-excellence/) - We never tire of mentioning how instrumental our people are to our success—because it is so incredibly true. Everything we have achieved and continue to do at Intelligencia AI and in the industry is because of our dedicated, intelligent, motivated professionals who tackle challenges and spot areas of opportunity every day with enthusiasm, creativity and - [Details in the Data: Therapeutic Area Insights Powered by Deep Domain Expertise and AI](https://www.intelligencia.ai/therapeutic-area-insights/) - Updated on Jan. 13, 2025 We invite you to join us as we deep-dive into our database and share unique and interesting insights into various therapeutic areas, including the current and potential future state of drug development for particular diseases. In our monthly series “In Focus: Therapeutic Area Insights,” we’ll select a disease from one - [Here’s How We’re Tapping Generative AI at Intelligencia AI](https://www.intelligencia.ai/generative-ai-llms-data-extraction/) - Authors: Afroditi Katika, Director of Product and Antonis Stampoulis, Director of Engineering As long as you haven’t lived under a rock for the last year and a half, you will have heard, read about, and possibly used the latest advancements in generative AI - large language models (LLMs). LLMs are now widely used for customer - [Part 3: AI Challenges | Forward-Looking Bias](https://www.intelligencia.ai/forward-looking-bias-ai-safeguards/) - Author: Dimitrios Markonis, Data Science Manager After discussing overfitting and the curse of dimensionality in parts 1 and 2 of our series AI Challenges and How We Safeguard Against Them, this third part focuses on another challenge associated with using AI, namely “forward-looking bias” and the steps we take to avoid it. Using data from the - [Part 2: AI Challenges | The Curse of Dimensionality ](https://www.intelligencia.ai/ai-challenges-dimensionality/) - Author: Dimitrios Markonis, Data Science Manager In part 1 of our series AI/ML Challenges and How Intelligencia Safeguards Against Them, we shared how overfitting can compromise AI-generated results and what we do at Intelligencia AI to avoid overfitting. We will discuss another closely related challenge in this second part of our series. This one has a - [Part 1: AI Challenges | Overfitting](https://www.intelligencia.ai/part-1-ai-challenges-and-how-we-safeguard-against-them-overfitting/) - Part 1: AI Challenges | Overfitting - [Q&A: Exploring the Future of AI in Healthcare With Panos Karelis](https://www.intelligencia.ai/future-of-ai-in-healthcare/) - This blog post originally appeared on Intelligent Health. Do you think the increased usage of Generative AI and LLMs will dramatically impact the healthcare industry, and if so, how? Even though they are in their infancy, generative AI and large language models (LLMs) have already significantly impacted the healthcare industry and will continue to mature. - [Inside Intelligencia AI: A Day in The Life With Mary Dimitraki, Scientific Associate in Clinical Data Excellence](https://www.intelligencia.ai/employee-profile-mary/) - We never tire of mentioning how instrumental our people are to our success—because it is so incredibly true. Everything we have achieved and continue to do at Intelligencia AI and in the industry is because of our dedicated, intelligent, motivated professionals who spot areas of opportunity and tackle challenges every day with enthusiasm, creativity and - [The AI Revolution in Healthcare – Key Takeaways From the 2024 AAIH Conference](https://www.intelligencia.ai/ai-healthcare-revolution-aaih/) - Author: Bara Badwan, Senior Data Scientist, Intelligencia AI I had the opportunity to attend the 2024 Alliance for Artificial Intelligence in Healthcare (AAIH) Conference and present our work on using AI to accurately predict promising biotechs and drug assets early and with greater confidence. This conference brought together experts from the healthcare, biotech and AI - [Inside Intelligencia AI: A Day in The Life With Dorita, Business Development Associate](https://www.intelligencia.ai/employee-profile-dorita/) - We never tire of mentioning how instrumental our people are to our success—because it is so incredibly true. Everything we have achieved and continue to do at Intelligencia AI and in the industry is because of our dedicated, intelligent, motivated professionals who tackle challenges and spot areas of opportunity every day with enthusiasm, creativity and - [Intelligencia AI Ranks No. 1819 on the 2024 Inc. 5000](https://www.intelligencia.ai/intelligencia-ai-inc-5000-2024/) - With Three-Year Revenue Growth of 287% AI-Powered Solution Provider Ranks Among America’s Fastest-Growing Private Companies NEW YORK, August 13, 2024 – Inc. revealed today that Intelligencia AI, a provider of AI-powered solutions that support data-driven decision-making in drug development, ranks No. 1819 on the 2024 Inc. 5000. The annual list recognizes the fastest-growing private companies - [Inside Intelligencia AI: A Day in The Life With Marina, Senior Scientific Associate in Clinical Data Excellence](https://www.intelligencia.ai/employee-profile-marina/) - We never tire of mentioning how instrumental our people are to our success—because it is so incredibly true. Everything we have achieved and continue to do at Intelligencia AI and in the industry is because of our dedicated, intelligent, motivated professionals who tackle challenges and spot areas of opportunity every day with enthusiasm, creativity and - [Inside Intelligencia AI: A Day in The Life With Andriana, Scientific Associate](https://www.intelligencia.ai/employee-profile-andriana/) - We never tire of mentioning how instrumental our people are to our success—because it is so incredibly true. Everything we have achieved and continue to do at Intelligencia AI and in the industry is because of our dedicated, intelligent, motivated professionals who tackle challenges and spot areas of opportunity every day with enthusiasm, creativity and - [ASH 2024: Validation of Our Accurate AI-Driven PTRS Assessments in Drug Development](https://www.intelligencia.ai/ash-2024-predictions-results/) - Authors: Eva Loizou, PhD, Customer Success Manager; Andreas Dimakakos, PhD, MBA, PMP, Director of Scientific Insights; Bara Badwan, PhD, Senior Data Scientist Before the 66th Annual ASH Annual Meeting and Exposition—the premier event in classical and malignant hematology—2024 kicked off in San Diego, we analyzed a subset of biotech companies with promising programs*. We analyzed - [2025 Pharma Predictions: AI, Health Tech, and Data Trends to Watch](https://www.intelligencia.ai/2025-pharma-predictions-ai-health-tech-and-data-trends-to-watch/) - 2024 was yet another landmark year in artificial intelligencia (AI), data, life sciences and the powerful combination of all three. From the first AI-discovered and AI-generated drug to enter clinical trials for idiopathic pulmonary fibrosis to AI advancements receiving two Nobel Prizes that will shape the future of medicine, as well as the surge of - [Leveraging AI in Regulatory Decision-Making: FDA Issues Draft Guidance](https://www.intelligencia.ai/fda-ai-guidance-regulation/) - The US Food and Drug Administration (FDA) kicked off the year with a major milestone: the release of its highly anticipated first draft guidance on the use of AI in drug and biological product development. Titled “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products,” this guidance focuses - [Inside Intelligencia AI: A Day in The Life With Konstantina, Product Liaison](https://www.intelligencia.ai/inside-intelligencia-ai-a-day-in-the-life-with-konstantina-product-liaison/) - We never tire of mentioning how instrumental our people are to our success—because it is so incredibly true. Everything we have achieved and continue to do at Intelligencia AI and in the industry is because of our dedicated, intelligent, motivated professionals who tackle challenges and spot areas of opportunity every day with enthusiasm, creativity and - [The Future of Pharma: How AI is Reshaping Drug Development & Strategic Decision-Making](https://www.intelligencia.ai/the-future-of-pharma-how-ai-is-reshaping-drug-development/) - Imagine a world where drug development is faster, more cost-effective, and tailored to individual patients. This vision is becoming a reality thanks to artificial intelligence (AI), which is transforming the pharmaceutical industry. AI streamlines drug development by rapidly analyzing vast amounts of data, enabling pharmaceutical companies to make more informed decisions, reduce costs, and accelerate - [Finding Signals in an Ocean of Noise – My Perspective on Driving Real Impact in Pharma in the Era of AI](https://www.intelligencia.ai/dimitris-agrafiotis-perspective-ai-in-pharma/) - Author: Dimitris Agrafiotis, Corporate Advisor to Intelligencia AI When people ask me what I do, I sometimes struggle to give a concise answer. I believe I can credibly call myself a scientist, an engineer, a business leader and, as of late, an investor, but in reality, I’m more than the sum of these parts. My - [The Healthcare Technology Report Announces The Top 100 Healthcare Technology Companies of 2024](https://www.intelligencia.ai/top-100-healthcare-tech-companies-2024/) - NEW YORK, Nov. 20, 2024 /PRNewswire-PRWeb/ -- The Healthcare Technology Report is pleased to announce its annual awards for The Top 100 Healthcare Technology Companies. This year's awardees were selected based on a methodical review of nomination submissions as well as further in-depth research into each candidate's products and solutions, corporate track record, management team caliber, and - [The Role of Biomarkers in Clinical Trials - and What We Learned from Baseball](https://www.intelligencia.ai/the-role-of-biomarkers-in-clinical-trials-and-what-we-learned-from-baseball/) - For over a century, teams selected baseball players based on subjective evaluations of their build, looks, on-field performance, and reputation. Then, mathematicians got involved. Specifically, statisticians used advanced statistical analyses to identify undervalued players who had great potential. This geeky approach to baseball is known as Moneyball and was popularized by the Oakland A’s, a - [Unlocking AI’s Potential in Drug Development: How Artificial Intelligence is the Future of Pharma](https://www.intelligencia.ai/ai-drug-development-recap/) - In a recent AI in Business Podcast episode, I discussed the key challenges and opportunities in AI in drug development, an area where innovation is rapidly transforming pharma. During my conversation, we explored several critical aspects of integrating AI into drug development processes, from overcoming adoption challenges to maximizing AI’s potential in pharma. Navigating the - [2025 ASCO Watchlist: What companies will rise to the top at ASCO based on our data and AI-driven insights?](https://www.intelligencia.ai/2025-asco-watchlist/) - ASCO is a barometer for the industry — and a catalyst for deeper insight ASCO remains the premier global forum for oncology clinical developments. At Intelligencia AI, we apply proprietary ML models to clinical trial data and program features to estimate the Probability of Technical and Regulatory Success (PTRS). Ahead of new clinical readouts, we - [How Can Drug Development Be De-Risked?](https://www.intelligencia.ai/how-can-drug-development-be-derisked/) - Drug development is notoriously risky. Out of roughly 10,000 early-stage compounds, only one ultimately succeeds. Even when a drug is approved, it may not earn back its development costs (Georgetown University). In 2022, the U.S. FDA Center for Drug Evaluation Research granted approval to just 37 new molecular entities, the smallest annual total since 2016, - [ASCO 2025: Demonstrating the Power of Predictive Analytics in Oncology Innovation](https://www.intelligencia.ai/2025-asco-results/) - Ahead of new clinical readouts at ASCO 2025, we utilized our AI-driven probability of technical and regulatory success (PTRS) assessments to identify oncology programs with strong potential, informed by both model insights and internal scientific expertise, to illustrate the predictive power of PTRS as an early indicator of success. We identified a focused set of - [Inside Intelligencia AI: A Day in The Life With Elena Hilario Martinez](https://www.intelligencia.ai/employee-profile-elena-martinez/) - We never tire of mentioning how instrumental our people are to our success—because it is so incredibly true. Everything we have achieved and continue to do at Intelligencia AI and in the industry is because of our dedicated, intelligent, motivated professionals who spot areas of opportunity and tackle challenges every day with enthusiasm, creativity and - [Moneyball for Drug Development: How Causal Inference can Increase the Probability of Success in Clinical Trials](https://www.intelligencia.ai/elevate-and-de-risk-your-drug-portfolio-strategy-with-ai/) - This conversation will cover perspectives and approaches to elevate portfolio strategy capabilities and de-risk drug development. - [Portfolio Strategy Focused Webinar: Elevate and De-Risk Your Drug Portfolio Strategy With AI](https://www.intelligencia.ai/portfolio-strategy-focused-webinar-elevate-and-de-risk-your-drug-portfolio-strategy-with-ai/) - Data-driven insights and AI can reduce clinical development risk and improve quantitative rigor in portfolio strategy. Panelists will share how they've used AI and insights tools to validate and calibrate the probability of technical and regulatory success (PTRS), support asset prioritization, and inform pipeline performance and strategic decisions about asset development. Speakers: John McGrath — - [How Causal Inference Can Increase the PoS in Clinical Trials](https://www.intelligencia.ai/how-causal-inference-can-increase-the-pos-in-clinical-trials/) - Join us for an insightful session featuring Gary Summers from GSK and Andrew Rainboldt from Intelligencia AI as they explore how cutting-edge causal inference techniques, applied to a decade of oncological clinical trial data, can revolutionize trial design and improve outcomes. Key takeaways How causal inference evaluates the impact of clinical design decisions, with a - [Fierce Pharma Week 2026: Unlocking Innovation in Life Sciences](https://www.intelligencia.ai/fierce-pharma-week-2026-unlocking-innovation-in-life-sciences/) - This September 14–17 at the Pennsylvania Convention Center in Philadelphia, over 3,000 pharmaceutical executives, strategic trailblazers, and cross-functional decision-makers will converge for Fierce Pharma Week 2026. As a proud official event sponsor, Intelligencia AI is stepping into the spotlight to ground these communities in radical operational certainty. Throughout the conference, our team will be leading - [UK Biotech Day 2026: Driving Strategic Cross-Border Life Science Alliances](https://www.intelligencia.ai/uk-biotech-day-2026-driving-strategic-cross-border-life-science-alliances/) - At the UK Biotech Day 2026, elite life science executives, pioneering R&D scientists, and global health investors gathered to accelerate breakthrough industry partnerships. Intelligencia AI joined this vibrant ecosystem to demonstrate how purpose-built machine learning removes legacy blind spots from asset evaluation. By equipping cross-functional dealmaking teams with objective, predictive data on a drug’s probability - [US Pharma Partnering Summit 2026: Transforming Drug Valuation](https://www.intelligencia.ai/transforming-drug-valuation-us-pharma-partnering-summit-2026/) - At the Pharma Partnering US Summit 2026, the nation's elite business development, licensing (BD&L), and investment executives converged to architect the next generation of biopharma alliances. Intelligencia AI stepped directly into the spotlight at this high-stakes forum, actively participating in a dynamic panel discussion centered on accelerating due diligence and asset optimization. On stage and - [BioPartnering Conference by BioNJ: Connecting Innovators, Investors And Industry](https://www.intelligencia.ai/connecting-innovators-investors-and-industry-biopartnering-conference-by-bionj/) - At the BioNJ BioPartnering Conference in New Jersey, global biopharma innovators, investors, and business development executives gathered to ignite the next wave of life science growth. With macroeconomic shifts placing an intense premium on capital efficiency, Intelligencia AI was on-site collaborating with regional ecosystem leaders to demonstrate how purpose-built machine learning removes legacy blind spots - [Fierce Pharma Engage – BD&L: Unlocking High-Stakes Clinical Value](https://www.intelligencia.ai/fierce-alliances-unlocking-high-stakes-clinical-value-at-fierce-pharma-engage-bdl/) - At the Fierce Pharma Engage 2026, over 600 life science directors and business development (BD&L) executives from companies like Genentech, Roche, and Sanofi gathered for highly curated, 1:1 strategic collaborations. As a proud event sponsor, Intelligencia AI anchored the innovation floor with a dedicated corporate booth. Throughout the summit, our team met with senior leadership - [2026 SDP Annual Conference: How Intelligencia AI Bridges the Data Gap](https://www.intelligencia.ai/high-stakes-certainty-how-intelligencia-ai-bridges-the-data-gap-at-sdp-20262026-sdp-annual-conference/) - Are modern biopharma executives handing over corporate strategy to black-box algorithms, or are they mastering the intersection of human wisdom and computational power to solidify pipeline value? At the 2026 SDP Annual Conference & Workshops hosted at the University of Massachusetts Boston, the global community of the Society of Decision Professionals gathered to decode a - [Emerging Technologies in Pharma & AI Summit](https://www.intelligencia.ai/emerging-technologies-in-pharma-ai-summit/) - Are today’s drug development pipelines evolving fast enough, or are legacy frameworks blinding teams to critical structural risks? At the monumental 1st Edition Emerging Technologies in Pharma & AI Summit 2026 in Vienna, visionary leaders gathered to decode the ultimate transformation of the pharmaceutical landscape. The core theme of the hybrid summit was undeniable: artificial - [Pharma Partnering 2026 EU Summit: Unlocking BD&L Value](https://www.intelligencia.ai/strategic-precision-unlocking-bdl-value-at-the-pharma-partnering-eu-summit/) - Explore how the Pharma Partnering EU Summit showcased the importance of objective asset valuation and how AI-driven insights empower decision-makers. - [19th Annual European Life Sciences CEO Forum](https://www.intelligencia.ai/19th-annual-european-life-sciences-ceo-forum/) - Explore the insights shared at the European Life Sciences CEO Forum on transforming biotech decision-making through predictive analytics and strategic partnering. - [Marcus Evans: Strategic Project & Portfolio Management for Pharma](https://www.intelligencia.ai/marcus-evans-strategic-project-portfolio-management-for-pharma/) - Discover how top pharma leaders optimize complex portfolios with data analytics and AI tools to accelerate therapy development. Join the industry forum now. - [Fierce Pharma Engage: BD&L Community (Sponsors)](https://www.intelligencia.ai/fierce-pharma-engage-bdl-community-sponsors/) - With general BD&L sessions and two tracks dedicated to asset-based and platform/non-molecule-driven deals, attendees can customize their learning experience and gain insights that will help them unlock the potential of a deal and drive a company’s competitive position in the marketplace. - [FT Live: U.S. Pharma and BioTech Summit](https://www.intelligencia.ai/ft-live-u-s-pharma-and-biotech-summit/) - The US biopharmaceutical industry faces relentless disruption. America leads the world in high-risk drug development, but how will President Trump's health policy picks stamp their authority? Advances in AI are accelerating innovation, but when will they generate returns and how will they transform workforces? Stay informed and connected by attending the US Pharma and Biotech Summit - [Marcus Evans: 19th Edition Project Portfolio and Resource Management Excellence for Pharma and Biotech](https://www.intelligencia.ai/marcus-evans-ppm-new-jersey/) - Researching, developing, and commercializing drugs, biologics and therapeutics require immense amounts of capital, time, and risk so ensuring projects are being undertaken, progressed, and paused or terminated is critical to optimizing the success of the portfolio and organization. Attendees will review novel and leading planning strategies and execution outcomes within project and portfolio management from - [Boston Society of Decision Professionals: R&D Strategy and Portfolio Management With a Focus on AI-Driven Innovation](https://www.intelligencia.ai/boston-society-of-decision-professionals-rd-strategy-and-portfolio-management-with-a-focus-on-ai-driven-innovation/) - Ever wonder how a global biopharma giant “PLai”s with AI to transform R&D strategy? Get ready to be inspired by the ingenious ways Sanofi integrates AI-driven insights to accelerate innovation and drive portfolio success. Join SDP Boston on April 29 at 6:00 PM at MIT Sloan to hear from Dr. Helen Merianos, SVP and Global Head of R&D Strategy and Portfolio Management - [Intelligencia AI Ranks No. 90 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies ](https://www.intelligencia.ai/inc-regionals-northeast-2024/) - Leading health tech and AI company has two-year revenue growth of 184% - [Intelligencia Raises $12M to Reduce the Risk of Clinical Research, Improve R&D Productivity, and Accelerate Scientific Breakthroughs](https://www.intelligencia.ai/press-release-1/) - NEW YORK & ATHENS, Greece & BASEL, Switzerland--(BUSINESS WIRE)-- Aug. 10 2021 - Intelligencia, whose AI-driven software platform enables pharmaceutical and biotechnology companies to revolutionize the drug development process and reduce risk, has raised $12M in order to continue to expand its product offering and customer base. Healthtech investor MTIP led the oversubscribed Series A ## Pages - [Home](https://www.intelligencia.ai/) - Revolutionize drug development with AI-driven insights. Enhance portfolio strategy, reduce risks, and make informed decisions. Our solutions predict success. - [Our People](https://www.intelligencia.ai/our-people/) - Meet Our People Behind Intelligencia AI is a global team of passionate experts spanning data science, life sciences, engineering, and commercial strategy. Meet the leadership and advisors driving our mission forward. Our Leadership Team Our global leadership team throughout the U.S. and Europe brings a wide range of skills, talents and experiences in the health, - [Portfolio Optimizer](https://www.intelligencia.ai/portfolio-optimizer/) - Intelligencia Portfolio OptimizerTM AI Clinical Development Software AI opens a new window of innovation for drug development. Using Portfolio Optimizer, you can optimize your drug pipeline, select promising drug candidates early, assess the competitive landscape, and make highly informed business development decisions. Discover More Explore an asset’s potential to clear all technical and regulatory hurdles - [TPP Insights](https://www.intelligencia.ai/tpp-insights/) - TPP Insights Ground Your Target Product Profile in the Evidence That Shapes the Market. A Target Product Profile is the strategic blueprint for a drug program — shaping development decisions, regulatory strategy, and commercial positioning.TPP Insights gives biopharma teams a standardized, continuously updated view of the comparators, clinical evidence, trial designs, and endpoints shaping an - [Competitive Landscapes](https://www.intelligencia.ai/competitive-landscapes/) - Competitive Landscapes See the Competitive Ecosystem. Today and Tomorrow. Competitive Landscapes gives biopharma teams a standardized, continuously updated view of the competitive ecosystem — from therapies and clinical programs competing today to the programs shaping tomorrow’s market.See the full picture in one connected view. Replace fragmented data, manual landscape-building, and outdated reports with timely intelligence - [Patents](https://www.intelligencia.ai/patents/) - Browse Intelligencia AI’s patented innovations driving advancements in AI-powered drug development and biotech decision-making. - [Dynamic Benchmarks](https://www.intelligencia.ai/dynamic-benchmarks/) - Dynamic Benchmarks We provide data visualizations into the competitive landscape. Dynamic Benchmarks puts you in the driver’s seat to take the lead in benchmark analysis to enhance existing processes. Discover More Find the Answers You Need to Inform Your Decision-Making Data spans back to 1990 and includes clinical programs based on industry-led, FDA-tracked interventional studies. - [Careers](https://www.intelligencia.ai/careers/) - We're looking for individuals who share our core values across various disciplines, including data science, bioinformatics, software engineering, and more. - [About Us](https://www.intelligencia.ai/about/) - Discover how Intelligencia AI revolutionizes drug development through data-driven, unbiased AI. Learn about our mission, leadership team, and core values. - [Who We Serve](https://www.intelligencia.ai/who-we-serve/) - Join forces with us, leading global pharmaceutical companies, to navigate the nuanced landscape of drug development. Benefit from our consultative approach. - [Content Hub](https://www.intelligencia.ai/content-hub/) - Discover cutting-edge AI-driven insights, case studies, and tools to enhance decision-making in pharma and biotech. Explore Intelligencia's expert resources. - [SaaS Products](https://www.intelligencia.ai/solutions/saas-products/) - Explore Intelligencia AI's patented SaaS platform — Portfolio Optimizer™ and Dynamic Benchmarks — delivering accurate, AI-driven probability of success assessments for drug development programs. - [Solutions](https://www.intelligencia.ai/solutions/) - Learn how Intelligencia AI's suite of solutions de-risks decisions, assesses drug success probability, and provides comprehensive clinical development insights. - [Peer-Reviewed Publications](https://www.intelligencia.ai/content-hub/peer-reviewed-publications/) - Description: Learn how Intelligencia AI leverages machine learning to transform drug development, enhancing efficiency & reducing risks. - [Inisights](https://www.intelligencia.ai/content-hub/insights/) - Description: Learn how Intelligencia AI leverages machine learning to transform drug development, enhancing efficiency & reducing risks. - [Spotlight](https://www.intelligencia.ai/spotlight/) - Where we're speaking, what we're winning, and how to catch us live. Press Releases Intelligencia AI Named to the Inc. 5000 2026 List of America’s Fastest-Growing Private Companies Aug 12 , 2026 Read More Intelligencia AI Honored as a Winner in the 2025 Artificial Intelligence Excellence Awards Jun 3 , 2025 Read More The Healthcare - [Events](https://www.intelligencia.ai/content-hub/events/) - Stay updated on Intelligencia's events and webinars. Learn how AI is transforming pharma and biotech with insights from industry leaders. - [Conference Intelligence](https://www.intelligencia.ai/content-hub/conference-intelligence-3/) - Explore expert articles on AI-driven solutions for pharma and biotech. Stay informed with insights on drug development, PTRS, and industry innovations. - [Press Releases](https://www.intelligencia.ai/content-hub/press-releases/) - Read press releases about Intelligencia AI's role in advancing drug development through AI, data analytics, and strategic partnerships. - [Perspectives](https://www.intelligencia.ai/content-hub/perspectives/) - Description: Learn how Intelligencia AI leverages machine learning to transform drug development, enhancing efficiency & reducing risks. - [Case Studies](https://www.intelligencia.ai/content-hub/case-studies/) - Description: Learn how Intelligencia AI leverages machine learning to transform drug development, enhancing efficiency & reducing risks. - [Articles](https://www.intelligencia.ai/content-hub/articles/) - Explore expert articles on AI-driven solutions for pharma and biotech. Stay informed with insights on drug development, PTRS, and industry innovations. - [Insights](https://www.intelligencia.ai/insights/) - Insights The Insight Drop | Beyond CD20: Autoimmunity’s Race for Deeper B-Cell Depletion Read More The Insight Drop | From Control to Reset: Autoimmune R&D Is Changing the Endgame Read More The Insight Drop | When AI Sounds Right: The Hidden Risk in Pharma R&D Read More The Insight Drop | B7-H3 (CD276): The ADC - [Webinars](https://www.intelligencia.ai/content-hub/webinars/) - Access on-demand webinars from Intelligencia. Learn how AI is revolutionizing decision-making in pharma and biotech with actionable insights. - [Seeker / Applicant](https://www.intelligencia.ai/seeker-applicant/) - Career Opportunity Thank you for expressing your interest in working at Intelligencia AI. Please fill out the form and we’ll be in touch. Full Name Email Phone Job Role LinkedIn Profile Upload CV/Resume * Fields marked with an asterisk are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service - [Privacy Notice](https://www.intelligencia.ai/privacy-notice/) - Privacy Notice Job Applicant Privacy Notice 1. Who We AreIntroductionWe, at Intelligencia Inc. (“Intelligencia”, “Company”, “we”, “us”, “our”), value your privacy and take serious steps to protect it. We have developed this Privacy Notice to inform you about our practices concerning the collection, use, and sharing of your personal data, when you apply for a - [Contact](https://www.intelligencia.ai/contact/) - Ready to leverage AI for enhanced clinical development and business decisions? Fill out the form and connect with us today. We're here to help you! - [Data Insights](https://www.intelligencia.ai/solutions/data-insights/) - Gain access to expertly curated and harmonized data for modeling, data science applications, and business intelligence in the biomedical field. - [Job Opening - Data Engineer (Sept. 2025)](https://www.intelligencia.ai/seeker-applicant/job-opening-data-engineer-sept-2025/) - As a Data Engineer at Intelligencia AI, you will architect, build, and launch scalable pipelines that transform fragmented datasets into a harmonized, single source of truth. - [No Access](https://www.intelligencia.ai/no-access/) - [dlm_no_access] - [FAQ](https://www.intelligencia.ai/faq/) - Answers to FAQs about the drug development process, and how Intelligencia AI's cutting-edge solutions leverage AI for de-risking drug development. - [Terms & Conditions](https://www.intelligencia.ai/terms-conditions/) - Under Construction For inquiries, please contact us at compliance@intelligencia.ai - [Thank You](https://www.intelligencia.ai/thank-you/) - Thank you for your interest. A member of our team will be in touch soon.Keep up with us on LinkedIn. - [Terms of Use](https://www.intelligencia.ai/terms-of-use/) - Terms of Use What types of personal data do we collect and use? Privacy notice Cookie statement Intellectual property rights Social media policy Termination Disclaimer – Limitation on liability 1. What types of personal data do we collect and use? 1.1. Our Website aims to shed light on our entity, the services we offer, and how ## Landing Pages - [Drug Development AI – Optimize PTRS](https://www.intelligencia.ai/drug-development-ai-optimize-ptrs/) - Optimize Your Portfolio, Today Experience frustration-free portfolio strategy Harness the power of AI for drug development to transform decision-making and optimize your pipeline. Intelligencia AI equips pharmaceutical companies with data-driven tools to enhance efficiency, reduce costs, and improve outcomes. Optimize PTRS With AI Leverage advanced analytics to calibrate the probability of technical and regulatory success ## My Templates - [New Post Template!](https://www.intelligencia.ai/?elementor_library=new-post-template) - New Post Template! June 15, 2026 Iro Mavrou TL;DR Probability of success (POS) is consistently overestimated in BD deals, distorting valuations before terms are signed. Most pharma partnerships fail; alliance management remains a critical and underweighted discipline. Big pharma is increasingly inclined to build internally rather than partner — unless someone else is faster. Valuation - [Default Kit](https://www.intelligencia.ai/?elementor_library=default-kit) - [Footer](https://www.intelligencia.ai/?elementor_library=elementor-footer-102) - Content Area - [New Events Post !](https://www.intelligencia.ai/?elementor_library=new-events-posts) - New Events Post ! At Intelligencia AI, we believe that transforming drug development starts from within. Our first internal GenAI Hackathon brought teams from across the organization together to explore how Generative AI can reshape everyday workflows, drive smarter automation, and unlock new levels of efficiency in how we work. From identifying practical use cases - [New Webinar Post !](https://www.intelligencia.ai/?elementor_library=elementor-single-post-3139) - New Webinar Post ! Data-driven insights and AI can reduce clinical development risk and improve quantitative rigor in portfolio strategy. Panelists will share how they’ve used AI and insights tools to validate and calibrate the probability of technical and regulatory success (PTRS), support asset prioritization, and inform pipeline performance and strategic decisions about asset development. - [Header](https://www.intelligencia.ai/?elementor_library=elementor-header-78) - Content Area - [Events Loop](https://www.intelligencia.ai/?elementor_library=events-loop) - PAST EVENT Events Loop , Read More - [Webinars Loop](https://www.intelligencia.ai/?elementor_library=webinars-loop) - PAST WEBINAR Webinars Loop , Online Read More Webinars Loop Read More - [Articles Loop](https://www.intelligencia.ai/?elementor_library=elementor-loop-item-3) - Articles Loop Feb 17 , 2025 Read More - [Elementor Loop Item #3047](https://www.intelligencia.ai/?elementor_library=elementor-loop-item-8) - [event filter](https://www.intelligencia.ai/?elementor_library=event-filter) - All Summit Conference Roundtable Forum Festival Hackathon - [content menu](https://www.intelligencia.ai/?elementor_library=content-menu) - [BD Director (2026)](https://www.intelligencia.ai/?elementor_library=bd-director-2026) - We are seeking a Business Development Director (Mid–Senior Level) with life sciencesexperience and a strong understanding of the clinical R&D landscape to join our globalBusiness Development team. This is a consultative, value-based sales role focused onengaging senior stakeholders across pharma and biotech organizations. You will work with scientific, clinical, portfolio strategy, and business development leadersto - [CXI position](https://www.intelligencia.ai/?elementor_library=cxi-position) - As the Director of Customer Experience & Insights, you will partner directly with the VP of Commercial to architect and lead the evolution of our client engagement model. You will serve as a key strategic operator, transforming how we deliver value to our partners and moving beyond traditional account management to become a strategic extension - [Elementor Single Post #2688](https://www.intelligencia.ai/?elementor_library=elementor-single-post-2688) - Back to Jobs Elementor Single Post #2688 Athens, London Apply AI-Enabled Development Intelligence Combined with Scientific and Commercial Expertise TL;DR Intelligencia AI identified ten oncology programs that are expected to generate meaningful data updates around ESMO 2026. For each program, the report evaluates the scientific rationale, clinical evidence generated to date, and the competitive landscape. - [Caerer Detail](https://www.intelligencia.ai/?elementor_library=elementor-single-post-2376) - Back to Jobs Caerer Detail Anywhere in the United States Apply AI-Enabled Development Intelligence Combined with Scientific and Commercial Expertise TL;DR Intelligencia AI identified ten oncology programs that are expected to generate meaningful data updates around ESMO 2026. For each program, the report evaluates the scientific rationale, clinical evidence generated to date, and the competitive - [Data Engineer Open Position](https://www.intelligencia.ai/?elementor_library=data-engneer-open-position) - Our Engineering team applies rigorous engineering practices and innovative design to our machine learning–driven platform, with the mission of accelerating the drug development process. This role will be a key contributor to the design and implementation of data pipelines that ingest billions of data points across hundreds of features—from publications, patents, genomics, and many other - [Job Posting](https://www.intelligencia.ai/?elementor_library=job-posting) - Legal Counsel- Job Description This is a fantastic opportunity for a mid-level experienced legal professional to join a dynamically scaling company in the life sciences and tech services sector as a founding member of its legal function. You will play a key role in shaping the company’s legal and operational foundation from the ground up. - [Product Page (Data)](https://www.intelligencia.ai/?elementor_library=product-page-data) - Expertly Curated and Harmonized Data You Can Trust Comprehensive clinical development and biological data empowers you to more precisely build models, advance data science applications, and drive business intelligence. Discover More Built on Best-in-Class Data and Proprietary Ontologies for Actionable Outcomes Coupled with scientific acumen, our consistent and standardized approach to clinical development data provides - [Featured Blog](https://www.intelligencia.ai/?elementor_library=elementor-loop-item-4) - Featured Blog Read More Read More - [Blog Single Post](https://www.intelligencia.ai/?elementor_library=single-post) - Blog Single Post Andreas Dimakakos February 19, 2025 AI-Enabled Development Intelligence Combined with Scientific and Commercial Expertise TL;DR Intelligencia AI identified ten oncology programs that are expected to generate meaningful data updates around ESMO 2026. For each program, the report evaluates the scientific rationale, clinical evidence generated to date, and the competitive landscape. Phase 1 - [Featured Press Release](https://www.intelligencia.ai/?elementor_library=elementor-loop-item-6) - Featured Press Release Featured Press Release Read More - [Featured Article Loop](https://www.intelligencia.ai/?elementor_library=elementor-loop-item-7) - Featured Article Featured Article Loop Read More - [Author Page](https://www.intelligencia.ai/?elementor_library=elementor-archive-2419) - Andreas Dimakakos Linkedin-in As the Director of Scientific Insights, Andreas analyzes our deep clinical data to extract meaningful insights and deliver advanced technical solutions to customers. He was previously the Director of Clinical Data at Intelligencia AI where he led the organization’s clinical data excellence team, a function consisting of 50+ biomedical MSc and PhD - [Author Page](https://www.intelligencia.ai/?elementor_library=elementor-archive-2375) - Template: Author Page - [Sort By](https://www.intelligencia.ai/?elementor_library=sort-by) - Sort By All Articles Blog Events Press Releases Webinars - [landingpage09july](https://www.intelligencia.ai/?elementor_library=landingpage09july) - Access Unbiased, AI-driven PTRS Assessments Having an accurate and reliable AI-driven probability of technical and regulatory success (PTRS) is vital for pharmaceutical companies when it comes to elevating decision-making and reducing risks. Improve Risk Assessments Use predictive tools and data-driven insights to identify and address potential hurdles early. Gain Strategic Insights Leverage AI coupled - [Testimonial](https://www.intelligencia.ai/?elementor_library=testimonial) - We did our competitive landscaping exercise and we are not aware of any other dataset that has been custom- built to address development risk. —Director, Global Pharmaceutical Company You are sitting on a goldmine. —Head of Statistics in Oncology Thank you for informing and enabling our portfolio strategy with a continuous stream of insights across - [Gerry Liaropoulos](https://www.intelligencia.ai/?elementor_library=gerry-liaropoulos) - Content Area - [Dimitrios Skaltsas](https://www.intelligencia.ai/?elementor_library=dimitrios-skaltsas) - Content Area - [Antonis Stampoulis, PhD](https://www.intelligencia.ai/?elementor_library=antonis-stampoulis-phd) - Content Area - [Alexandra Ferraro](https://www.intelligencia.ai/?elementor_library=alexandra-ferraro) - Content Area - [Violetta Kalathaki](https://www.intelligencia.ai/?elementor_library=violetta-kalathaki) - Content Area - [Andreas Beroutsos](https://www.intelligencia.ai/?elementor_library=andreas-beroutsos) - Content Area - [Simo Kamppari](https://www.intelligencia.ai/?elementor_library=simo-kamppari) - Content Area - [Pete Georgiadis](https://www.intelligencia.ai/?elementor_library=pete-georgiadis) - Content Area - [Aristotelis Tsirigos](https://www.intelligencia.ai/?elementor_library=aristotelis-tsirigos) - Content Area - [Aiman Shalabi](https://www.intelligencia.ai/?elementor_library=aiman-shalabi) - Content Area - [Vassilis Gorgoulis](https://www.intelligencia.ai/?elementor_library=vassilis-gorgoulis) - Content Area - [Névine Zariffa](https://www.intelligencia.ai/?elementor_library=nevine-zariffa) - Content Area - [Phoebe Prosalika](https://www.intelligencia.ai/?elementor_library=phoebe-prosalika) - Content Area - [Nikos Papadopoulos](https://www.intelligencia.ai/?elementor_library=nikos-papadopoulos) - Content Area - [Maria Georganaki](https://www.intelligencia.ai/?elementor_library=maria-georganaki) - Content Area - [Panos Karelis](https://www.intelligencia.ai/?elementor_library=panos-karelis) - Content Area - [Elena Valkana](https://www.intelligencia.ai/?elementor_library=elena-valkana) - Content Area - [Heracles Kasimis](https://www.intelligencia.ai/?elementor_library=heracles-kasimis) - Content Area - [Edoardo Madussi](https://www.intelligencia.ai/?elementor_library=edoardo-madussi) - Content Area - [Webinar Single Post](https://www.intelligencia.ai/?elementor_library=webinar-single-post) - Webinar Single Post AI-Enabled Development Intelligence Combined with Scientific and Commercial Expertise TL;DR Intelligencia AI identified ten oncology programs that are expected to generate meaningful data updates around ESMO 2026. For each program, the report evaluates the scientific rationale, clinical evidence generated to date, and the competitive landscape. Phase 1 programs feature some of oncology’s - [Featured Article](https://www.intelligencia.ai/?elementor_library=elementor-loop-item-5) - Featured Article Read More - [Elementor Error 404 #2194](https://www.intelligencia.ai/?elementor_library=elementor-error-404-2194) - 404 Something is missing… We couldn’t find the page you’re looking for. Return Home - [Home Backup March](https://www.intelligencia.ai/?elementor_library=home-backup-march) - Patent Received for Accurate and Transparent Probability of Success Leading the way in de-risking clinical development with Al Read More Al Drug Development Company Increase the Probability of Success in Drug Development By harnessing the power of data and Al Explore Our Solutions Uncover Actionable Insights for Clinical Development With Al Let's Talk - [Blog with image](https://www.intelligencia.ai/?elementor_library=elementor-loop-item-1899) - 17 Feb Blog with image Read More - [Drug Development AI Template](https://www.intelligencia.ai/?elementor_library=drug-development-ai-template) - Revolutionizing Drug Development With AI Harness the power of AI for drug development to transform decision-making and optimize your pipeline. Intelligencia AI equips pharmaceutical companies with data-driven tools to enhance efficiency, reduce costs, and improve outcomes. Optimize PTRS With AI Leverage advanced analytics to calibrate the probability of technical and regulatory success (PTRS) for better - [Event Single Post](https://www.intelligencia.ai/?elementor_library=event-single-post) - – Event Single Post AI-Enabled Development Intelligence Combined with Scientific and Commercial Expertise TL;DR Intelligencia AI identified ten oncology programs that are expected to generate meaningful data updates around ESMO 2026. For each program, the report evaluates the scientific rationale, clinical evidence generated to date, and the competitive landscape. Phase 1 programs feature some of - [Press Releases Single Post](https://www.intelligencia.ai/?elementor_library=elementor-single-post-1982) - Press Release Press Releases Single Post February 20, 2025 AI-Enabled Development Intelligence Combined with Scientific and Commercial Expertise TL;DR Intelligencia AI identified ten oncology programs that are expected to generate meaningful data updates around ESMO 2026. For each program, the report evaluates the scientific rationale, clinical evidence generated to date, and the competitive landscape. Phase - [Let’s Talk](https://www.intelligencia.ai/?elementor_library=lets-talk) - Discover How Artificial Intelligence Can Improve Your Clinical Development and Commercial Decision-Making Let’s Talk - [Elementor Loop Item #1893](https://www.intelligencia.ai/?elementor_library=elementor-loop-item-2) - [Elementor Loop Item #1890](https://www.intelligencia.ai/?elementor_library=elementor-loop-item) - Elementor Loop Item #1890 ## MailPoet Page - [MailPoet Page](https://www.intelligencia.ai/?mailpoet_page=subscriptions) - [mailpoet_page] - [MailPoet Page](https://www.intelligencia.ai/?mailpoet_page=captcha) - [mailpoet_page] ## Our Team - [Gerry Tsoukalas](https://www.intelligencia.ai/our-team/gerry-tsoukalas/) - As a Scientific Advisor, Gerry brings to Intelligencia a rare combination of deep technical rigor and firsthand experience at the frontier of AI, markets, and institutional design. Gerry is Professor of Artificial Intelligence at the University of Oxford, Deputy Dean for Human-Centered AI and Innovation, and Research Co-Director of the AI & Society Lab at - [Panos Karelis](https://www.intelligencia.ai/our-team/panos-karelis-2/) - Panos Karelis is VP, Head of Commercial at Intelligencia AI, where he leads the company's global commercial organization and oversees the Center of Insights Excellence. He works closely with pharmaceutical and biotech partners to help them make more informed R&D, portfolio, and strategic investment decisions through AI-powered predictive analytics and bespoke data-driven insights. He brings - [Jeremy Brody](https://www.intelligencia.ai/our-team/jeremy-brody/) - As a Corporate Advisor, Jeremy brings to Intelligencia nearly three decades of experience at the intersection of healthcare, technology, data, and strategy. Through his work with high-growth healthcare companies and institutional investors, he has developed a unique perspective on how data-driven innovation is transforming life sciences, market access, and healthcare decision-making. Jeremy is the Founder - [Dimitris Agrafiotis](https://www.intelligencia.ai/our-team/dimitris-agrafiotis/) - As a corporate advisor, Dimitris helps guide the organization on digital transformation, artificial intelligence, data strategy, and innovation across the drug development lifecycle. Dimitris has more than 30 years of experience spanning pharmaceutical R&D, biotechnology, healthcare technology, and data science. He currently serves as a Director at Arsenal Capital Partners, where he leads digital, data, - [Heracles Kasimis](https://www.intelligencia.ai/our-team/heracles-kasimis/) - As VP of Engineering, Heracles oversees the development and maintenance of the company's external facing and supportive software architecture. This includes the cloud infrastructure, data extraction pipelines, Intelligencia AI’s SaaS platform, analytics/reporting toolchains, and APIs for programmatic data consumption. Prior to Intelligencia AI, he worked for more than 12 years as a software engineer in - [Stephen Cho](https://www.intelligencia.ai/our-team/stephen-cho/) - As a member of Intelligencia AI’s Scientific Advisory Board, Stephen Cho helps guide the organization on portfolio strategy, decision-making frameworks, and the application of data-driven approaches to drug development and R&D investment. Stephen’s career spans the intersection of science, policy, and portfolio management, with more than two decades of leadership experience across pharmaceutical research, clinical - [Sirin Neyzi](https://www.intelligencia.ai/our-team/sirin-neyzi-2/) - As VP of Finance, Sirin leads the company’s finance function across financial planning, fundraising, and investor and lender relations. She brings over fifteen years of experience in the finance industry, including more than a decade at Citigroup in New York, where she rose to Managing Director in Corporate Banking and advised major Healthcare, Consumer & - [Maria Georganaki](https://www.intelligencia.ai/our-team/maria-georganaki-2/) - Maria is the VP of Product & Data at Intelligencia AI where she leads multidisciplinary teams and drives product development strategies that align with the company’s vision. She is passionate about leveraging the power of artificial intelligence to deliver cutting-edge solutions that empower drug development stakeholders to make data-driven decisions. As a molecular cancer biologist - [Jon Moser](https://www.intelligencia.ai/our-team/jon-moser/) - As Chief Product Officer, Jon leads product and engineering at Intelligencia AI, with a focus on translating the company's clinical intelligence capabilities into products that pharmaceutical teams trust and rely on. Jon brings close to twenty years of experience working at the intersection of forecasting, data science and biopharma intelligence. He is deeply committed to - [Gerry Liaropoulos](https://www.intelligencia.ai/our-team/gerry-liaropoulos/) - As the Chief AI Officer, Gerry leads a multidisciplinary team of computational scientists, statisticians and informatics experts. This group develops proprietary machine-learning algorithms and focuses on integrating new information. They also focus on the development of new features that improve the accuracy and usability of the predictions and explore new data-driven solutions to help the - [Simo Kamppari, MBA](https://www.intelligencia.ai/our-team/simo-kamppari-mba/) - As a corporate advisor, Simo supports Intelligencia AI’s continued business growth, as the company continues to evolve and navigates various business dynamics. As an engineer, Simo has a passion for building products and businesses. Since 2010, he has been actively investing in and supporting the growth of a range of companies in the technology and - [Pete Georgiadis, MBA](https://www.intelligencia.ai/our-team/pete-georgiadis-mba/) - Pete Georgiadis serves as a corporate advisor to Intelligencia AI. He is a serial entrepreneur, experienced operator and the founder and CEO of Synetro Group, a Chicago-based private investment and strategic advisory firm. Since founding Synetro in 2000, he has led the firm’s investment in over 50 companies and has personally helped build more than - [Aristotelis Tsirigos, PhD](https://www.intelligencia.ai/our-team/aristotelis-tsirigos-phd/) - As a scientific advisor, Dr. Tsirigos has played a pivotal role in Intelligencia AI’s development of a cutting-edge machine-learning model designed to forecast the technical and regulatory success of clinical trials. He continues to provide guidance and expertise to the growing company, leveraging his extensive knowledge and experience in machine learning and bioinformatics. Dr. Tsirigos - [Vassilis Gorgoulis](https://www.intelligencia.ai/our-team/vassilis-gorgoulis/) - In his advisor role for Intelligencia AI, Professor Gorgoulis is involved with the supervision of projects associated with drug repurposing and machine learning to evaluate molecular targets and mechanisms in oncology. He and his group have teamed up with Intelligencia AI’s bioinformatics and data science team to provide solutions that involve AI techniques in order - [Aiman Shalabi, PharmD, MBA](https://www.intelligencia.ai/our-team/aiman-shalabi-pharmd-mba/) - As a scientific advisor to Intelligencia AI, Aiman helps guide the organization on overall strategy and how the health tech company can help pharmaceutical organizations bring better medicines to patients, faster. Aiman has 25 years of experience in healthcare innovation. He is currently the managing director and CEO of a healthcare holding/investment company funded by - [Névine Zariffa, M. Math](https://www.intelligencia.ai/our-team/nevine-zariffa-m-math/) - Névine Zariffa is the Chair of Intelligencia AI’s Scientific Advisory Board. In this role, she provides strategic guidance on the company’s product development and roadmap while leading and coordinating the activities of the scientific advisory board. She is a highly accomplished thought leader in the fields of biostatistics and data science with extensive experience across - [Dimitrios Skaltsas, MBA](https://www.intelligencia.ai/our-team/dimitrios-skaltsas-mba/) - As the CEO and co-founder of Intelligencia AI, Dimitrios Skaltsas leads the AI-based technology organization’s business and investment growth strategy, while overseeing key functional areas of the multidisciplinary, growing team. In 2021, the company completed its Series A funding and was named one of Forbes’s Top AI Companies to Watch. During this time, Dimitrios played ## Categories - [Press Releases](https://www.intelligencia.ai/category/press-releases/) - [Events](https://www.intelligencia.ai/category/events/) - [Articles](https://www.intelligencia.ai/category/articles/) - [Webinars](https://www.intelligencia.ai/category/webinars/) - [Insights](https://www.intelligencia.ai/category/insights/) - [Case Studies](https://www.intelligencia.ai/category/case-studies/) - [Conference Intelligence](https://www.intelligencia.ai/category/conference-intelligence/) - [Perspectives](https://www.intelligencia.ai/category/perspectives/) - [Peer-Reviewed Publication](https://www.intelligencia.ai/category/peer-reviewed-publication/) ## Tags - [Conference](https://www.intelligencia.ai/tag/conference/) - [Summit](https://www.intelligencia.ai/tag/summit/) - [Hackathon](https://www.intelligencia.ai/tag/hackathon/) - [Roundtable](https://www.intelligencia.ai/tag/roundtable/) - [Festival](https://www.intelligencia.ai/tag/festival/) - [Forum](https://www.intelligencia.ai/tag/forum/) ## Our Team Categories - [Leadership Team](https://www.intelligencia.ai/our-team-category/leadership-team/) - [Scientific and Corporate Advisors](https://www.intelligencia.ai/our-team-category/scientific-and-corporate-advisors/)